Akt antibody

    • Catalog No.:YT6111
    • Applications:WB,ELISA
    • Reactivity:Human,Mouse,Rat
      • Gene Name:
      • AKT1 PKB RAC
      • Protein Name:
      • RAC-alpha serine/threonine-protein kinase (EC 2.7.11.1) (Protein kinase B) (PKB) (Protein kinase B alpha) (PKB alpha) (Proto-oncogene c-Akt) (RAC-PK-alpha)
      • Human Gene Id:
      • 207
      • Human Swiss Prot No:
      • P31749
      • Mouse Swiss Prot No:
      • P31750
      • Immunogen:
      • Synthesized peptide derived from human Akt
      • Specificity:
      • This antibody detects endogenous levels of Akt antibody
      • Formulation:
      • Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
      • Source:
      • Rabbit
      • Dilution:
      • WB 1:500-2000, ELISA 1:10000-20000
      • Purification:
      • The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
      • Concentration:
      • 1 mg/ml
      • Storage Stability:
      • -20°C/1 year
      • Other Name:
      • RAC-alpha serine/threonine-protein kinase (EC 2.7.11.1) (Protein kinase B) (PKB) (Protein kinase B alpha) (PKB alpha) (Proto-oncogene c-Akt) (RAC-PK-alpha)
      • Observed Band(KD):
      • 55
      • Background:
      • AKT serine/threonine kinase 1(AKT1) Homo sapiens The serine-threonine protein kinase encoded by the AKT1 gene is catalytically inactive in serum-starved primary and immortalized fibroblasts. AKT1 and the related AKT2 are activated by platelet-derived growth factor. The activation is rapid and specific, and it is abrogated by mutations in the pleckstrin homology domain of AKT1. It was shown that the activation occurs through phosphatidylinositol 3-kinase. In the developing nervous system AKT is a critical mediator of growth factor-induced neuronal survival. Survival factors can suppress apoptosis in a transcription-independent manner by activating the serine/threonine kinase AKT1, which then phosphorylates and inactivates components of the apoptotic machinery. Mutations in this gene have been associated with the Proteus syndrome. Multiple alternatively spliced transcript variants have been found for this gene. [provided by RefSeq, Jul 2011]
      • Function:
      • catalytic activity:ATP + a protein = ADP + a phosphoprotein.,disease:Defects in AKT1 are associated with breast cancer (BC) [MIM:114480]. BC is an extremely common malignancy, affecting one in eight women during their lifetime.,disease:Defects in AKT1 are associated with colorectal cancer (CRC) [MIM:114500].,disease:Defects in AKT1 are associated with susceptibility to ovarian cancer [MIM:604370]; also called susceptibility to familial breast-ovarian cancer type 1 (BROVCA1).,domain:Binding of the PH domain to the phosphatidylinositol 3-kinase alpha (PI(3)K) results in its targeting to the plasma membrane.,domain:The AGC-kinase C-terminal mediates interaction with THEM4.,enzyme regulation:Three specific sites, one in the kinase domain (Thr-308) and the two other ones in the C-terminal regulatory region (Ser-473 and Tyr-474), need to be phosphorylated for its full activation.,function:Gene
      • Subcellular Location:
      • nucleus,nucleoplasm,cytoplasm,mitochondrion,spindle,cytosol,plasma membrane,cell-cell junction,microtubule cytoskeleton,vesicle,ciliary basal body,protein complex,postsynapse,
      • Expression:
      • Epithelium,Eye,Foreskin,Muscle,Ovary,Placenta,

      Jin, Zi-Qi, et al. "Higenamine enhances the antitumor effects of cucurbitacin B in breast cancer by inhibiting the interaction of AKT and CDK2." Oncology reports 40.4 (2018): 2127-2136.
      Catalog No.:YT6111

      • Products Images
      • Western blot analysis of various lysate, antibody was diluted at 1000. Secondary antibody(catalog#:RS0002) was diluted at 1:20000